vs

Side-by-side financial comparison of BV Financial, Inc. (BVFL) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $10.5M, roughly 1.2× BV Financial, Inc.). BV Financial, Inc. runs the higher net margin — 45.6% vs -1398.3%, a 1443.9% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 9.2%). BV Financial, Inc. produced more free cash flow last quarter ($18.8M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 11.1%).

Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

BVFL vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.2× larger
RNA
$12.5M
$10.5M
BVFL
Growing faster (revenue YoY)
RNA
RNA
+424.8% gap
RNA
434.0%
9.2%
BVFL
Higher net margin
BVFL
BVFL
1443.9% more per $
BVFL
45.6%
-1398.3%
RNA
More free cash flow
BVFL
BVFL
$175.7M more FCF
BVFL
$18.8M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
11.1%
BVFL

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BVFL
BVFL
RNA
RNA
Revenue
$10.5M
$12.5M
Net Profit
$4.8M
$-174.4M
Gross Margin
Operating Margin
66.9%
-1513.5%
Net Margin
45.6%
-1398.3%
Revenue YoY
9.2%
434.0%
Net Profit YoY
146.2%
-117.0%
EPS (diluted)
$0.52
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BVFL
BVFL
RNA
RNA
Q4 25
$10.5M
Q3 25
$10.0M
$12.5M
Q2 25
$9.9M
$3.8M
Q1 25
$9.2M
$1.6M
Q4 24
$9.7M
$3.0M
Q3 24
$10.0M
$2.3M
Q2 24
$9.5M
$2.0M
Q1 24
$8.5M
$3.5M
Net Profit
BVFL
BVFL
RNA
RNA
Q4 25
$4.8M
Q3 25
$3.7M
$-174.4M
Q2 25
$2.9M
$-157.3M
Q1 25
$2.1M
$-115.8M
Q4 24
$2.0M
$-102.3M
Q3 24
$3.8M
$-80.4M
Q2 24
$3.4M
$-70.8M
Q1 24
$2.6M
$-68.9M
Operating Margin
BVFL
BVFL
RNA
RNA
Q4 25
66.9%
Q3 25
51.5%
-1513.5%
Q2 25
39.9%
-4448.7%
Q1 25
29.4%
-8360.9%
Q4 24
29.5%
-4069.6%
Q3 24
52.4%
-4200.9%
Q2 24
49.6%
-4040.4%
Q1 24
42.1%
-2178.6%
Net Margin
BVFL
BVFL
RNA
RNA
Q4 25
45.6%
Q3 25
37.2%
-1398.3%
Q2 25
29.0%
-4089.3%
Q1 25
22.9%
-7360.0%
Q4 24
20.2%
-3439.5%
Q3 24
38.0%
-3441.7%
Q2 24
35.8%
-3461.8%
Q1 24
30.1%
-1943.4%
EPS (diluted)
BVFL
BVFL
RNA
RNA
Q4 25
$0.52
Q3 25
$0.41
$-1.27
Q2 25
$0.29
$-1.21
Q1 25
$0.21
$-0.90
Q4 24
$0.18
$-0.80
Q3 24
$0.35
$-0.65
Q2 24
$0.32
$-0.65
Q1 24
$0.24
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BVFL
BVFL
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$55.7M
$350.2M
Total DebtLower is stronger
$35.0M
Stockholders' EquityBook value
$183.8M
$1.9B
Total Assets
$912.2M
$2.1B
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BVFL
BVFL
RNA
RNA
Q4 25
$55.7M
Q3 25
$63.5M
$350.2M
Q2 25
$56.3M
$243.9M
Q1 25
$70.8M
$254.2M
Q4 24
$70.5M
$219.9M
Q3 24
$94.1M
$370.2M
Q2 24
$90.6M
$575.8M
Q1 24
$78.8M
$471.4M
Total Debt
BVFL
BVFL
RNA
RNA
Q4 25
$35.0M
Q3 25
$35.0M
Q2 25
$35.0M
Q1 25
$49.9M
Q4 24
$49.9M
Q3 24
$34.8M
Q2 24
$34.8M
Q1 24
$34.8M
Stockholders' Equity
BVFL
BVFL
RNA
RNA
Q4 25
$183.8M
Q3 25
$190.2M
$1.9B
Q2 25
$198.0M
$1.2B
Q1 25
$198.1M
$1.3B
Q4 24
$195.5M
$1.4B
Q3 24
$209.7M
$1.5B
Q2 24
$205.5M
$1.2B
Q1 24
$201.8M
$830.9M
Total Assets
BVFL
BVFL
RNA
RNA
Q4 25
$912.2M
Q3 25
$909.4M
$2.1B
Q2 25
$908.3M
$1.4B
Q1 25
$921.9M
$1.5B
Q4 24
$911.8M
$1.6B
Q3 24
$892.7M
$1.6B
Q2 24
$897.2M
$1.3B
Q1 24
$892.5M
$951.5M
Debt / Equity
BVFL
BVFL
RNA
RNA
Q4 25
0.19×
Q3 25
0.18×
Q2 25
0.18×
Q1 25
0.25×
Q4 24
0.26×
Q3 24
0.17×
Q2 24
0.17×
Q1 24
0.17×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BVFL
BVFL
RNA
RNA
Operating Cash FlowLast quarter
$19.0M
$-156.2M
Free Cash FlowOCF − Capex
$18.8M
$-156.9M
FCF MarginFCF / Revenue
178.2%
-1257.6%
Capex IntensityCapex / Revenue
2.2%
5.7%
Cash ConversionOCF / Net Profit
3.96×
TTM Free Cash FlowTrailing 4 quarters
$34.0M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BVFL
BVFL
RNA
RNA
Q4 25
$19.0M
Q3 25
$8.4M
$-156.2M
Q2 25
$2.7M
$-199.7M
Q1 25
$4.4M
$-124.8M
Q4 24
$16.1M
$-99.9M
Q3 24
$6.1M
$-65.6M
Q2 24
$1.5M
$-65.0M
Q1 24
$4.6M
$-70.4M
Free Cash Flow
BVFL
BVFL
RNA
RNA
Q4 25
$18.8M
Q3 25
$8.4M
$-156.9M
Q2 25
$2.6M
$-203.0M
Q1 25
$4.2M
$-128.6M
Q4 24
$15.5M
$-103.8M
Q3 24
$6.0M
$-67.3M
Q2 24
$1.4M
$-65.5M
Q1 24
$4.1M
$-71.3M
FCF Margin
BVFL
BVFL
RNA
RNA
Q4 25
178.2%
Q3 25
84.0%
-1257.6%
Q2 25
26.1%
-5277.1%
Q1 25
46.0%
-8174.3%
Q4 24
160.0%
-3491.0%
Q3 24
59.6%
-2881.8%
Q2 24
15.2%
-3204.6%
Q1 24
48.4%
-2012.3%
Capex Intensity
BVFL
BVFL
RNA
RNA
Q4 25
2.2%
Q3 25
0.1%
5.7%
Q2 25
1.4%
86.9%
Q1 25
2.4%
238.6%
Q4 24
6.3%
131.7%
Q3 24
1.0%
72.9%
Q2 24
0.6%
26.0%
Q1 24
5.1%
25.8%
Cash Conversion
BVFL
BVFL
RNA
RNA
Q4 25
3.96×
Q3 25
2.26×
Q2 25
0.95×
Q1 25
2.11×
Q4 24
8.23×
Q3 24
1.60×
Q2 24
0.44×
Q1 24
1.77×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons